These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 23849826)

  • 1. Evidence of epidermal growth factor receptor expression in uveal melanoma: inhibition of epidermal growth factor-mediated signalling by Gefitinib and Cetuximab triggered antibody-dependent cellular cytotoxicity.
    Amaro A; Mirisola V; Angelini G; Musso A; Tosetti F; Esposito AI; Perri P; Lanza F; Nasciuti F; Mosci C; Puzone R; Salvi S; Truini M; Poggi A; Pfeffer U
    Eur J Cancer; 2013 Oct; 49(15):3353-65. PubMed ID: 23849826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
    Qin B; Ariyama H; Baba E; Tanaka R; Kusaba H; Harada M; Nakano S
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):577-84. PubMed ID: 16532343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.
    Dominguez-Escrig JL; Kelly JD; Neal DE; King SM; Davies BR
    Clin Cancer Res; 2004 Jul; 10(14):4874-84. PubMed ID: 15269164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines.
    Pino MS; Shrader M; Baker CH; Cognetti F; Xiong HQ; Abbruzzese JL; McConkey DJ
    Cancer Res; 2006 Apr; 66(7):3802-12. PubMed ID: 16585207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor competes with EGF receptor inhibitors to induce cell death in EGFR-overexpressing tumor cells.
    Song JY; Lee SW; Hong JP; Chang SE; Choe H; Choi J
    Cancer Lett; 2009 Oct; 283(2):135-42. PubMed ID: 19380191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of epidermal growth factor receptor in the metastasis of intraocular melanomas.
    Ma D; Niederkorn JY
    Invest Ophthalmol Vis Sci; 1998 Jun; 39(7):1067-75. PubMed ID: 9620065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. c-Met, epidermal growth factor receptor, and insulin-like growth factor-1 receptor are important for growth in uveal melanoma and independently contribute to migration and metastatic potential.
    Wu X; Zhou J; Rogers AM; Jänne PA; Benedettini E; Loda M; Hodi FS
    Melanoma Res; 2012 Apr; 22(2):123-32. PubMed ID: 22343486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.
    Gerdes CA; Nicolini VG; Herter S; van Puijenbroek E; Lang S; Roemmele M; Moessner E; Freytag O; Friess T; Ries CH; Bossenmaier B; Mueller HJ; Umaña P
    Clin Cancer Res; 2013 Mar; 19(5):1126-38. PubMed ID: 23209031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Responses of human colorectal tumor cells to treatment with the anti-epidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor gefitinib.
    Cunningham MP; Thomas H; Fan Z; Modjtahedi H
    Cancer Res; 2006 Aug; 66(15):7708-15. PubMed ID: 16885373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance.
    Knowlden JM; Jones HE; Barrow D; Gee JM; Nicholson RI; Hutcheson IR
    Breast Cancer Res Treat; 2008 Sep; 111(1):79-91. PubMed ID: 17902048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for Cetuximab-mediated therapy in recurrent/metastatic disease.
    Bellone S; Frera G; Landolfi G; Romani C; Bandiera E; Tognon G; Roman JJ; Burnett AF; Pecorelli S; Santin AD
    Gynecol Oncol; 2007 Sep; 106(3):513-20. PubMed ID: 17540437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
    Li B; Chang CM; Yuan M; McKenna WG; Shu HK
    Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implications of EGFR inhibition in ovarian cancer cell proliferation.
    Bull Phelps SL; Schorge JO; Peyton MJ; Shigematsu H; Xiang LL; Miller DS; Lea JS
    Gynecol Oncol; 2008 Jun; 109(3):411-7. PubMed ID: 18423824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
    Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
    Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of a dimeric Affibody molecule (ZEGFR:1907)2 targeting EGFR in combination with radiation in colon cancer cell lines.
    Häggblad Sahlberg S; Spiegelberg D; Lennartsson J; Nygren P; Glimelius B; Stenerlöw B
    Int J Oncol; 2012 Jan; 40(1):176-84. PubMed ID: 21879255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells.
    Amin DN; Bielenberg DR; Lifshits E; Heymach JV; Klagsbrun M
    Microvasc Res; 2008 May; 76(1):15-22. PubMed ID: 18440031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines.
    Kurai J; Chikumi H; Hashimoto K; Yamaguchi K; Yamasaki A; Sako T; Touge H; Makino H; Takata M; Miyata M; Nakamoto M; Burioka N; Shimizu E
    Clin Cancer Res; 2007 Mar; 13(5):1552-61. PubMed ID: 17332301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII.
    Pedersen MW; Pedersen N; Ottesen LH; Poulsen HS
    Br J Cancer; 2005 Oct; 93(8):915-23. PubMed ID: 16189524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.